Compare IDAI & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDAI | COSM |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Other Pharmaceuticals |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 13.5M |
| IPO Year | 2022 | 2009 |
| Metric | IDAI | COSM |
|---|---|---|
| Price | $2.38 | $0.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 39.3K | ★ 334.7K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.50 | 45.58 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $54,426,402.00 |
| Revenue This Year | $103.06 | $20.69 |
| Revenue Next Year | $140.06 | $53.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.97 |
| 52 Week Low | $1.43 | $0.28 |
| 52 Week High | $5.28 | $1.32 |
| Indicator | IDAI | COSM |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 33.28 |
| Support Level | $2.35 | $0.30 |
| Resistance Level | $2.82 | $0.50 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 41.43 | 29.78 |
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.